Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

The new acquisition from Boston Pharmaceuticals adds to a wave of dealmaking undertaken by GSK to build its liver disease ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

From my colleague Jason Mast: The first ever patient has been treated with prime editing, a powerful technology for making ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

Altimmune, a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, entered into an agreement with Hercules Capital, for up ...

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.